Population pharmacokinetics of digoxin in thai pediatric patients

Journal of the Medical Association of Thailand

Volumn 92, Issue 10, 2009, Pages 1324-1335

  Preechagoon, Yupaporn ^a   Somsaard, Peeraya ^a,b   Petcharattana, Setthasiri ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

Digoxin; Heart failure; Pediatrics; Pharmacokinetics; Population

Indexed keywords

DIGOXIN;

ADOLESCENT; AGE DETERMINATION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; THAILAND;

ANTI-ARRHYTHMIA AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIGOXIN; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; MODELS, STATISTICAL; THAILAND;

EID: 70350441987     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1977; 2: 1-16.
2. Park MK. Use of digoxin in infants and children, with specific emphasis on dosage. J Pediatr 1986; 108: 871-877
3. Kay JD, Colan SD, Graham TP Jr. Congestive heart failure in pediatric patients. Am Heart J 2001; 142: 923-928 (Pubitemid 33016213)
4. Latifi S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. Prog Pediatr Cardiol 2000; 12: 57-79.
5. Tett SE, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Info J 1998; 32: 693-710.
6. Keller F, Rietbrock N. Bioavailability of digoxin: some pitfalls and problems. Int J Clin Pharmacol Biopharm 1977; 15: 549-556 (Pubitemid 8241131)
7. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5: 485-527.
8. Grasela TH, Sheiner LB. Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 1991; 19: 25S-36S.
9. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users' Guide. San Francisco: NONMEM Project Group, University of California; 1994.
10. Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992; 44: 761-765 (Pubitemid 23111548)
11. Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol 2001; 57: 19-24. (Pubitemid 32391407)
12. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512
13. Hastreiter AR, van der Horst RL, Voda C, Chow-Tung E. Maintenance digoxin dosage and steady-state plasma concentration in infants and children. J Pediatr 1985; 107: 140-146 (Pubitemid 15006862)
14. Koren G. Therapeutic drug monitoring principles in the neonate. National Academy of CLinical Biochemistry. Clin Chem 1997; 43: 222-227 (Pubitemid 27024420)
15. McEvoy GK. AHFS drug information 2005. Bethesda: American Society of Health-System Pharmacists; 2005.
16. Suematsu F, Minemoto M, Yukawa E, Higuchi S. Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. J Clin Pharm Ther 1999; 24: 203-208 (Pubitemid 29354037)
17. Wettrell G, Andersson KE. Clinical pharmacokinetics of digoxin in infants. Clin Pharmacokinet 1977; 2: 17-31.
18. Wells TG, Young RA, Kearns GL. Age-related differences in digoxin toxicity and its treatment. Drug Saf 1992; 7: 135-151
19. Martin-Suarez A, Falcao AC, Outeda M, Hernandez FJ, Gonzalez MC, Quero M, et al. Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit 2002; 24: 742-745 (Pubitemid 35379528)
20. el Desoky ES, Madabushi R, Amry S, Bhattaram VA, Derendorf H. Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? Am J Ther 2005;12:320-327
21. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol 1997;37:92-100. (Pubitemid 27131539)
22. Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Clin Pharmacokinet 2001; 40: 773-781 (Pubitemid 33027890)
23. Nagaraja NV, Park YJ, Jeon S, Sands CD, Derendorf H. Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther 2000; 38: 291-297 (Pubitemid 30346225)
24. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479 (Pubitemid 8224518)
25. Waldorff S, Andersen JD, Heeboll-Nielsen N, Nielsen OG, Moltke E, Sorensen U, et al. Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 1978; 24: 162-167
26. Cleland JG, Dargie HJ, Pettigrew A, Gillen G, Robertson JI. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. Am Heart J 1986; 112: 130-135 (Pubitemid 16066266)
27. Mazurek W, Haczynski J. Interaction of captopril and digoxin [abstract]. Pol Tyg Lek 1993; 48: 834-835
28. Douste-Blazy P, Blanc M, Montastruc JL, Conte D, Cotonat J, Galinier F. Is there any interaction between digoxin and enalapril? Br J Clin Pharmacol 1986; 22: 752-753
29. Iraz M, Kurcer Z, Ozdemir R, Guven A, Sezgin AT, Olmez E. Comparative effects of losartan and enalapril on serum digoxin levels in patients with congestive heart failure. Eur J Gen Med 2004; 1: 12-15
30. Mutnick AH. Digoxin. In: Schumacher GE, editor. Therapeutic drug monitoring. Norwalk, Connecticut: Appleton & Lange; 1995: 469-491